Navigation Links
Panmira and FLAP LLCs Spun Out of Amira Pharmaceuticals
Date:9/8/2011

SAN DIEGO, Sept. 8, 2011 /PRNewswire/ -- Panmira Pharmaceuticals, LLC and FLAP, LLC, today announced their formation around certain assets spun out immediately preceding the acquisition of Amira Pharmaceuticals, Inc. (Amira) by Bristol-Myers Squibb Company (NYSE: BMY).  Panmira Pharmaceuticals received a number of assets, including Amira's DP2 antagonists, AM211 and AM461, both of which have successfully completed Phase I clinical studies.  FLAP, LLC is a non-operating company with rights to future milestones and royalties from Amira's 2008 licensing deal with GlaxoSmithKline related to the 5-lipoxygenase-activating protein (FLAP) inhibitor program.

"Now that we have successfully completed the sale of Amira to Bristol-Myers Squibb Company, a subset of the former Amira team will focus on completing our partnership efforts for the DP2 program," said Bob Baltera, Chief Executive Officer of Panmira Pharmaceuticals.  "We believe that spinning out these assets will be the best way to maximize their value for Amira's shareholders, and we look forward to accomplishing this goal."

Hari Kumar, Ph.D., Chief Business Officer, added, "Clinical trial results have demonstrated a dose proportional pharmacodynamic (PD) effect and good safety profiles for both AM211 and AM461.  These compounds are primed and ready for Phase II exploration in a number of clinical settings, including asthma, chronic obstructive pulmonary disease (COPD) and eosinophillic esophagitis.  We look forward to having the right partner to help make these plans come to fruition."

While there are no DP2 selective antagonists approved for therapeutic use, there is a strong scientific rationale for the target to be a novel, potentially disease-modifying treatment of asthma, COPD and allergic rhinitis. DP2, also known as chemoattractant receptor-homologous molecule expressed in Th2 lymphocytes (CRTH2), is a high affinity receptor for the prostaglandin D2 and is impli
'/>"/>

SOURCE Panmira Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Amira Pharmaceuticals to Present Preclinical Data on AM152 , an LPA1 Receptor Antagonist, at the Annual Meeting of the American Thoracic Society
2. Amira Pharmaceuticals Announces Completion of Phase 1 Clinical Study for AM152, A Novel LPA1 Receptor Antagonist
3. Amira Pharmaceuticals Receives Orphan Drug Status for a Novel LPA1 Antagonist, AM152, for the Treatment of Idiopathic Pulmonary Fibrosis
4. Amira Pharmaceuticals Announces the Nomination of an Orally Available Pre-Clinical Candidate in a New LPA-Related Program, an Autotaxin Inhibitor
5. Amira Pharmaceuticals Announces Initiation of Phase I Clinical Trial for AM152, A Novel LPA1 Antagonist
6. Amira Pharmaceuticals Announces IND Submission for Novel LPA1 Antagonist, AM152, for Potential Use in Fibrotic Diseases
7. Amira Pharmaceuticals Named One of Most Promising Biotech Companies by FierceBiotechs Annual Fierce 15
8. Visage Imaging Releases Amira 5.3
9. Amira Announces AM103 and AM803 Patent Grant in the United Kingdom
10. Amira Announces Second DP2 Antagonist Patent Grant in the United Kingdom
11. Anti-Fibrotic Data from Amira Pharmaceuticals LPA1 Receptor Antagonist Program Published in the British Journal of Pharmacology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... 2015 Roche,s Bloodhound technology is on ... in hematology testing, according to Kalorama Information.  The ... of its Bloodhound digital cell imaging technology –as ... hematology analyzer – is notable as a ... current leader CellaVision, but also compete more broadly ...
(Date:7/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/nlfg34/cancer ) has announced the addition of ... - Forecast to 2020" report to their offering. ... in 2020 from an estimated $7.1 Billion in 2015, growing at ... North America , followed by Europe ... World (RoW). The cancer diagnostics market in Asia ...
(Date:7/2/2015)... Numotion,s Board of Directors and Mike ... Feitel has joined the Company as Chief Financial ... successful 18 year career at GE serving in executive ... productivity to result in significant industry leading growth and ... Officer for GE Healthcare Global Services, a $5B P&L ...
Breaking Medicine Technology:Kalorama: With Bloodhound, Roche Closes in on High-Growth Hematology Segment 2Kalorama: With Bloodhound, Roche Closes in on High-Growth Hematology Segment 3Global Cancer Diagnostics Market Report 2015 - Technology, Imaging and by Applications Forecasts to 2020 for the $13 Billion Industry 2Numotion Names Tamas Feitel Chief Financial Officer 2
... the leading developer of radiology workflow solutions, today ... a joint venture between Inland Imaging and Providence ... system with Medicalis, federated productivity and quality platform ... these two proven solutions will enable radiologists who ...
... 2010 Orion HealthCorp , Inc., a leader in ... announced today that its President and CEO, Terrence L. Bauer, ... 25 Entrepreneur list. Bauer ranked No. 12 on the list. ... Ingwersen, Business-to-Business compiles the list each year, recognizing ...
Cached Medicine Technology:Medicalis Acquires RadWorkFlow from Inland Imaging and Providence Health Care 2Medicalis Acquires RadWorkFlow from Inland Imaging and Providence Health Care 3Business-to-Business Magazine Names Orion HealthCorp CEO as Top 25 Entrepreneur for 2010 2
(Date:7/2/2015)... ... ... sweetFrog Enterprises, LLC. is pleased to announce the opening of its newest location ... The premium frozen yogurt chain was listed as #22 on the Inc. 500 list ... New Albany, MS 38652, will have a grand opening event on July 4, 2015 ...
(Date:7/2/2015)... ... July 02, 2015 , ... sweetFrog Enterprises, LLC. is pleased to ... the 19th sweetFrog store located in the Lone Star State. The premium frozen yogurt ... in 2014. , The store, which opened July 1 at Duke’s Travel Plaza, is ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... for her introduction of the Stop Overdose Stat (S.O.S.) Act of 2015 on ... Reed (D-R.I.), this Act seeks to decrease drug overdose – especially of heroin ...
(Date:7/2/2015)... RI (PRWEB) , ... July 02, 2015 , ... Many ... safety in mind. That’s why Amica Insurance is sharing some tips to ... Commission (CPSC), approximately 230 people go to the emergency room daily with fireworks-related injuries ...
(Date:7/2/2015)... ... ... Patrick Achebe realized that the gift of poetry was fully in him, as beautiful phrases ... and three years later he was publishing an entire book of poetry. He knew there ... have always believed that the best way to lift yourself up, is in the effort ...
Breaking Medicine News(10 mins):Health News:sweetfrog Opens First Location in Mississippi 2Health News:sweetFrog Expands Texas Footprint with Location in Canton 2Health News:AAPCC Supports the Stop Overdose Stat Act of 2015 2Health News:AAPCC Supports the Stop Overdose Stat Act of 2015 3Health News:6 Fireworks Safety Tips from Amica Insurance 2Health News:Patrick Achebe Releases Debut Book, Whispering Waves: Poems for Everyday Grace 2
... NY, Sept. 18 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - GENova ... the relationship with Bridge BioResearch PLC and unconditionally retract ... announced that Mr. Anders Bogh Jensen, Chief Science Officer ... the GENova,s Scientific Advisory Board. , , About ...
... tolerate pills, researchers say , FRIDAY, Sept. 18 (HealthDay ... promise in animal testing and could become an alternative ... the drugs, U.S. researchers report. , Oral erectile dysfunction ... called phosphodiesterase 5 (PDE5) inhibitors, are widely used and ...
... , , , ... EFJI ) today announced that it received notice from ... its common stock had closed below $1.00 for 30 consecutive business ... 5450(a)(1). In accordance with the NASDAQ Marketplace Rules, the Company ...
... , , , , ... NxStage Medical, Inc. (Nasdaq: NXTM ), a leading manufacturer ... Wells, 57, has embarked on his third annual "Grandpa,s Road Trip" ... machine, the NxStage System One provides Mr. Wells the opportunity to ...
... SOMERSET, N.J., Sept. 18 TeamStaff, Inc. ... and administrative staffing services, today announced that on September 15, ... of The Nasdaq Global Market (Nasdaq) stating that for the ... not maintained a minimum market value of publicly held shares ...
... Calif., Sept. 18 Solta Medical, Inc. (Nasdaq: SLTM ... that it will present at the Maxim Group Growth Conference to ... New York Hotel in New York, NY. The Company,s presentation ... Stephen J. Fanning, Chairman, President and Chief Executive Officer, will ...
Cached Medicine News:Health News:Topical Cream for Erectile Dysfunction Shows Promise 2Health News:NxStage Patient Takes Dialysis Machine on Third Annual Patient Good-Will Tour 2Health News:NxStage Patient Takes Dialysis Machine on Third Annual Patient Good-Will Tour 3Health News:TeamStaff Receives Nasdaq Deficiency Notice Related to the Market Value of Its Publicly Held Shares 2Health News:TeamStaff Receives Nasdaq Deficiency Notice Related to the Market Value of Its Publicly Held Shares 3Health News:Solta Medical to Present at the Maxim Group Growth Conference 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: